Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Rhea-AI Summary

Disc Medicine (NASDAQ:IRON) has announced a conference call scheduled for Tuesday, January 21, at 8:00 am EST to discuss feedback from its Type C meeting with the FDA regarding bitopertin in Erythropoietic Protoporphyria (EPP). The company, which focuses on developing treatments for serious hematologic diseases, will host the discussion to share insights from their regulatory interaction.

Interested participants can register for the event through the Events and Presentations section of Disc Medicine's investor relations website. This meeting represents a significant step in the development process for bitopertin as a potential treatment for EPP patients.

WATERTOWN, Mass., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its Type C meeting on bitopertin in EPP with the U.S. Food and Drug Administration (FDA). The conference call will be held on Tuesday, January 21, at 8:00 am EST.

Conference Call Information

Please register for the event on the Events and Presentations page of Disc’s website at https://ir.discmedicine.com/.

About Bitopertin

Bitopertin is an investigational, clinical-stage, orally administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis. GlyT1 is a membrane transporter expressed on developing red blood cells and is required to supply sufficient glycine for heme biosynthesis and support erythropoiesis. Disc is planning to develop bitopertin as a potential treatment for a range of hematologic diseases including erythropoietic porphyrias, where it has potential to be the first disease-modifying therapy. Bitopertin has been studied in multiple clinical trials in patients with EPP, including the Phase 2 open-label BEACON trial, the Phase 2 double-blind, placebo-controlled AURORA trial, and an open-label extension HELIOS trial.

Bitopertin is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide. Disc obtained global rights to bitopertin under a license agreement from Roche in May 2021.

About Erythropoietic Protoporphyria (EPP)

Erythropoietic protoporphyria (EPP), including X-linked Protoporphyria (XLP), is a rare, debilitating and potentially life-threatening disease caused by mutations that affect heme biosynthesis, resulting in the accumulation of a toxic, photoactive intermediate called protoporphyrin IX (PPIX). This causes severe reactions when patients are exposed to sunlight, characterized by excruciating pain, edema, burning sensations and potential blistering and disfigurement. PPIX also accumulates in the hepatobiliary system and can result in complications including gallstones, cholestasis, and liver damage in 20-30% of patients and in extreme cases liver failure. Current standard of care involves extreme measures to avoid sunlight, including restricting outdoor activities to nighttime, use of protective clothing and opaque shields, and pain management. This has a significant impact on the psychosocial development, quality of life, and daily activities of patients, particularly in young children and families. There is currently no cure for EPP and only one FDA-approved therapy, a surgically implanted synthetic hormone designed to stimulate melanin production called Scenesse® (afamelanotide).

About Disc Medicine

Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Media Contact

Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com

Investor Relations Contact

Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com

FAQ

When is Disc Medicine's (IRON) conference call about the FDA Type C meeting for bitopertin?

Disc Medicine's conference call is scheduled for Tuesday, January 21, 2025, at 8:00 am EST.

What is the purpose of Disc Medicine's (IRON) Type C meeting with the FDA?

The Type C meeting was held to discuss bitopertin as a treatment for Erythropoietic Protoporphyria (EPP), with the feedback to be shared during the conference call.

How can investors join Disc Medicine's (IRON) conference call about bitopertin?

Investors can register for the conference call through the Events and Presentations page on Disc Medicine's website at ir.discmedicine.com.

What therapeutic area is Disc Medicine (IRON) focusing on with bitopertin?

Disc Medicine is developing bitopertin for Erythropoietic Protoporphyria (EPP), which falls under their focus on treatments for serious hematologic diseases.